LTZ Therapeutics
LTZ Therapeutics62About
What does LTZ Therapeutics do?
LTZ Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies that empower myeloid cells to enhance anti-tumor immunity. Their Universal Myeloid Cell Engager (U-MCETM) platform aims to address unmet clinical needs in oncology and autoimmune diseases by directly engaging myeloid cells to activate killing mechanisms and reprogram the tumor microenvironment.
What is LTZ Therapeutics's revenue?
StartupHub estimates LTZ Therapeutics's annual revenue at $9.9M (range $3.3M to $28.4M, 34% confidence), based on comparable companies in the sector.
What is LTZ Therapeutics's valuation?
StartupHub estimates LTZ Therapeutics's effective valuation at $302.9M (range $190.0M to $456.0M, 23% confidence), based on comparable companies in the sector.
How much funding has LTZ Therapeutics raised?
LTZ Therapeutics has raised a total of $76M in funding. The most recent round on record is Series B.
Where is LTZ Therapeutics headquartered?
LTZ Therapeutics is headquartered in Redwood City, California, USA.
When was LTZ Therapeutics founded?
LTZ Therapeutics was founded in 2021.
What industry does LTZ Therapeutics operate in?
LTZ Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Biotech, Drug Discovery, Clinical Trials.
No comments yet. Be the first to share your take.